ICAD - Icad Inc Stock Price, Fair Value and News

1.49USD-0.05 (-3.25%)Delayed as of 22 Apr 2024, 11:04 am ET

Market Summary

USD1.49-0.05

Delayedas of 22 Apr 2024, 11:04 am

-3.25%

ICAD Stock Price

View Fullscreen

ICAD RSI Chart

ICAD Valuation

Market Cap

40.9M

Price/Earnings (Trailing)

-8.43

Price/Sales (Trailing)

2.16

EV/EBITDA

-2.83

Price/Free Cashflow

-6.94

ICAD Price/Sales (Trailing)

ICAD Profitability

EBT Margin

-37.27%

Return on Equity

-14.5%

Return on Assets

-11.7%

Free Cashflow Yield

-14.4%

ICAD Fundamentals

ICAD Revenue

Revenue (TTM)

18.9M

Rev. Growth (Yr)

27.35%

Rev. Growth (Qtr)

-22.15%

ICAD Earnings

Earnings (TTM)

-4.8M

Earnings Growth (Yr)

166.4%

Earnings Growth (Qtr)

249.56%

Breaking Down ICAD Revenue

52 Week Range

1.053.97

(Low)(High)

Last 7 days

-7.7%

Last 30 days

0.7%

Last 90 days

1.3%

Trailing 12 Months

7.6%

How does ICAD drawdown profile look like?

ICAD Financial Health

Current Ratio

4.4

ICAD Investor Care

Shares Dilution (1Y)

5.07%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	20.2M	18.5M	18.2M	18.9M
2022	32.5M	32.3M	27.3M	21.9M
2021	31.8M	34.0M	36.3M	33.6M
2020	31.1M	29.4M	28.6M	29.7M
2019	26.1M	27.2M	28.9M	31.3M
2018	27.6M	27.4M	26.6M	25.6M
2017	27.1M	26.1M	27.1M	28.1M
2016	34.4M	30.6M	27.0M	26.3M
2015	48.6M	50.1M	47.1M	41.6M
2014	33.7M	35.6M	39.9M	43.9M
2013	29.9M	31.6M	31.8M	33.1M
2012	27.7M	26.9M	27.1M	28.3M
2011	25.4M	25.9M	28.4M	28.7M
2010	0	26.9M	25.8M	24.6M
2009	0	0	0	28.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Icad Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 31, 2023	brown dana r	bought	52,000	1.3	40,000	see remarks
Sep 12, 2022	go jonathan	sold	-106,653	2.73751	-38,960	chief technology officer
Sep 12, 2022	go jonathan	acquired	102,150	2.27	45,000	chief technology officer
Mar 03, 2022	irish timothy norris	bought	25,465	4.63	5,500	-
Feb 08, 2022	sassine andy	sold	-54,900	5.49	-10,000	-
Feb 07, 2022	sassine andy	sold	-52,600	5.26	-10,000	-
Jan 31, 2022	go jonathan	acquired	58,000	2.9	20,000	chief technology officer
Jan 07, 2022	sassine andy	sold	-60,700	6.07	-10,000	-
Jan 06, 2022	sassine andy	sold	-62,000	6.2	-10,000	-
Jan 05, 2022	stevens stacey m	bought	104,927	6.17	17,006	president

Which funds bought or sold ICAD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 12, 2024	waypoint wealth counsel	unchanged	-	-1,600	16,100	0.01%
Apr 11, 2024	SALEM INVESTMENT COUNSELORS INC	new	-	118,986	118,986	-%
Apr 10, 2024	Banque Cantonale Vaudoise	unchanged	-	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	2.98	-303,214	1,924,620	-%
Mar 05, 2024	GREENWOOD CAPITAL ASSOCIATES LLC	added	98.38	455,877	1,142,300	0.07%
Feb 26, 2024	Virtu Financial LLC	new	-	24,000	24,000	-%
Feb 15, 2024	JANE STREET GROUP, LLC	sold off	-100	-66,992	-	-%
Feb 14, 2024	Royal Bank of Canada	reduced	-21.72	-	1,000	-%
Feb 14, 2024	CITADEL ADVISORS LLC	added	14,447	86,063	86,774	-%
Feb 14, 2024	PERRITT CAPITAL MANAGEMENT INC	reduced	-26.05	-141,139	230,571	0.13%

Are Funds Buying or Selling ICAD?

Are funds buying ICAD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ICAD

No. of Funds

Unveiling Icad Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	granahan investment management, llc	1.62%	426,409	SC 13G/A
Jul 24, 2023	granahan investment management, llc	5.94%	1,510,981	SC 13G/A
Mar 15, 2023	pura vida investments, llc	5.02%	1,277,214	SC 13G
Feb 14, 2023	granahan investment management, llc	11.20%	2,849,124	SC 13G/A
Dec 09, 2022	hirschman orin	2.1%	531,981	SC 13G/A
Nov 02, 2022	granahan investment management, llc	10.2%	2,578,670	SC 13G/A
Jul 08, 2022	blackrock inc.	1.5%	371,417	SC 13G
Jul 06, 2022	hirschman orin	5.6%	1,404,898	SC 13G
Feb 14, 2022	granahan investment management, llc	9.49%	2,382,896	SC 13G
Feb 11, 2022	portolan capital management, llc	0%	0	SC 13G/A

Recent SEC filings of Icad Inc

View All Filings

Date Filed	Form Type	Document
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Mar 29, 2024	10-K	Annual Report
Mar 12, 2024	8-K	Current Report
Feb 26, 2024	8-K	Current Report
Feb 26, 2024	4	Insider Trading
Feb 26, 2024	3	Insider Trading

Peers (Alternatives to Icad Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	186.2B	40.1B	-3.77%	-2.76%	32.53	4.64	-8.12%	-17.45%
BDX	67.7B	19.5B	-1.53%	-10.57%	53.87	3.47	4.02%	-22.04%
ALGN	22.5B	3.9B	-9.16%	-15.16%	50.45	5.81	3.42%	23.09%
BAX	20.0B	14.8B	-5.62%	-8.72%	7.55	1.35	2.12%	209.17%
MID-CAP
ATR	9.2B	3.5B	-0.49%	17.01%	32.33	2.64	4.97%	18.89%
HSIC	9.1B	12.3B	-5.22%	-14.61%	21.9	0.74	-2.44%	-22.68%
BIO	8.2B	2.7B	-16.90%	-39.13%	-12.81	3.06	-4.68%	82.43%
XRAY	6.3B	4.0B	-8.41%	-25.34%	-47.02	1.6	1.10%	85.84%
AXNX	3.4B	366.4M	-2.66%	12.41%	-562.64	9.32	33.86%	89.83%
PDCO	2.3B	6.6B	-4.93%	-3.92%	12.05	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.2B	3.2B	-14.38%	-20.49%	-1.83	0.39	7.73%	-1066.14%
ANIK	383.7M	166.7M	0.86%	-5.21%	-4.64	2.3	6.67%	-456.34%
ANGO	250.7M	324.0M	11.81%	-29.38%	-1.3	0.77	-3.19%	-337.41%
APYX	45.7M	52.3M	-28.65%	-55.25%	-2.44	0.87	17.61%	19.28%
AEMD	3.8M	3.7M	-10.98%	147.46%	-0.31	1.02	5.77%	8.23%

Icad Inc News

Latest updates

Icad Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-22.1%	3,171,000	4,073,000	5,865,000	5,778,000	2,490,000	4,359,000	7,575,000	7,523,000	7,807,500	9,361,000	7,826,000	8,644,000	10,451,000	7,129,000	5,567,000	6,551,000	9,381,000	7,857,000	7,329,000	6,773,000	6,954,000
Gross Profit	0.9%	3,553,500	3,521,000	4,349,000	4,130,000	3,107,000	3,704,000	5,491,000	5,312,000	5,704,000	6,712,000	5,538,000	6,289,000	7,462,000	5,025,000	4,357,000	4,510,000	7,165,000	6,054,000	5,726,000	5,282,000	5,410,000
Operating Expenses	-10.9%	4,223,000	4,740,000	6,272,000	8,055,000	4,594,000	6,869,000	8,605,000	8,834,000	9,851,500	8,893,000	8,409,000	7,822,000	8,957,000	6,714,000	6,668,000	8,403,000	9,110,000	8,014,000	7,184,000	6,316,000	8,204,000
S&GA Expenses	11.2%	1,663,000	1,495,000	2,112,000	2,857,000	1,806,500	2,761,000	3,435,000	3,565,000	4,396,000	3,886,000	3,429,000	3,424,000	4,094,000	2,979,000	2,631,000	3,608,000	4,353,000	3,588,000	3,120,000	2,573,000	2,421,000
R&D Expenses	-24.9%	861,000	1,147,000	1,263,000	2,281,000	289,000	1,407,000	2,367,000	2,275,000	2,449,000	2,285,000	2,268,000	2,192,000	2,176,000	1,849,000	1,878,000	2,211,000	2,520,000	2,485,000	2,139,000	2,127,000	2,014,000
EBITDA Margin	17.2%	-0.36	-0.43	-0.51	-0.52	-0.49	-0.50	-0.39	-0.40	-0.32	-0.23	-0.23	-0.21	-0.57	-	-	-	-	-	-	-	-
Interest Expenses	-	15,000	-	-	-	-1,500	7,000	-	9,000	-	-	29,000	112,000	116,000	115,000	115,000	130,000	180,000	193,000	202,000	209,000	131,000
Income Taxes	75.0%	7,000	4,000	4,000	5,000	-116,500	-	-	1,000	1,000	-	-	-	4,000	3,000	5,000	26,000	10,000	6,000	19,000	8,000	-1,000
Earnings Before Taxes	52.9%	-487,000	-1,033,000	-1,746,000	-3,773,000	-1,359,500	-3,103,000	-3,118,000	-3,544,000	-4,145,000	-2,176,000	-3,280,000	-1,643,000	-1,599,000	-1,794,000	-2,393,000	-11,786,000	-3,338,000	-2,950,000	-3,511,000	-3,709,000	-3,345,000
EBT Margin	15.7%	-0.37	-0.44	-0.52	-0.53	-0.49	-0.51	-0.40	-0.40	-0.33	-0.24	-0.24	-0.23	-0.59	-	-	-	-	-	-	-	-
Net Income	249.6%	2,055,000	-1,374,000	-1,750,000	-3,778,000	-3,095,000	-3,898,000	-3,118,000	-3,545,000	-4,146,000	-2,176,000	-3,280,000	-1,643,000	-1,603,000	-1,797,000	-2,398,000	-11,812,000	-3,348,000	-2,956,000	-3,530,000	-3,717,000	-3,344,000
Net Income Margin	32.4%	-0.26	-0.38	-0.47	-0.49	-0.45	-0.54	-0.40	-0.40	-0.33	-0.24	-0.24	-0.23	-0.59	-	-	-	-	-	-	-	-
Free Cashflow	-7.2%	-1,886,000	-1,760,000	-590,000	-1,650,000	-3,299,000	-2,751,000	-2,664,000	-4,600,000	-1,684,000	-2,374,000	-2,088,000	-3,825,000	-1,088,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-9.6%	41.00	46.00	45.00	48.00	52.00	55.00	58.00	59.00	62.00	66.00	67.00	75.00	56.00	48.00	48.00	38.00	42.00	42.00	41.00	33.00	32.00
Current Assets	-8.2%	30.00	32.00	31.00	34.00	38.00	42.00	45.00	48.00	50.00	53.00	54.00	62.00	42.00	36.00	36.00	25.00	29.00	29.00	30.00	22.00	21.00
Cash Equivalents	13.8%	22.00	19.00	19.00	20.00	21.00	25.00	27.00	30.00	34.00	36.00	38.00	47.00	27.00	23.00	24.00	14.00	15.00	17.00	20.00	11.00	12.00
Inventory	-7.6%	1.00	1.00	4.00	5.00	2.00	6.00	5.00	5.00	4.00	3.00	3.00	2.00	3.00	3.00	3.00	2.00	3.00	2.00	2.00	2.00	2.00
Net PPE	41.9%	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Goodwill	0%	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00
Liabilities	-45.9%	8.00	15.00	15.00	16.00	17.00	18.00	17.00	15.00	16.00	16.00	16.00	22.00	25.00	22.00	21.00	23.00	37.00	33.00	30.00	29.00	25.00
Current Liabilities	-40.9%	7.00	11.00	12.00	13.00	13.00	15.00	14.00	14.00	15.00	15.00	14.00	14.00	17.00	14.00	13.00	14.00	19.00	17.00	15.00	15.00	13.00
Shareholder's Equity	7.7%	33.00	31.00	30.00	32.00	35.00	38.00	41.00	44.00	47.00	50.00	51.00	53.00	31.00	25.00	26.00	15.00	5.00	8.00	11.00	5.00	7.00
Retained Earnings	0.8%	-271	-273	-272	-270	-266	-263	-259	-256	-253	-249	-246	-243	-241	-240	-238	-236	-224	-220	-218	-214	-210
Additional Paid-In Capital	0.1%	306	306	304	303	303	303	302	302	301	300	299	298	274	267	266	252	231	230	230	220	219
Accumulated Depreciation	5.4%	1.00	1.00	2.00	2.00	1.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	6.00	7.00	6.00	6.00
Shares Outstanding	0.4%	26.00	26.00	25.00	25.00	25.00	25.00	25.00	25.00	25.00	25.00	24.00	24.00	22.00	-	-	-	-	-	-	-	-
Float	-	-	-	39.00	-	-	-	93.00	-	-	-	400,890	-	-	-	209	-	-	-	113	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	8.2%	-1,451	-1,580	-405	-1,528	-3,130	-2,651	-2,560	-4,449	-1,547	-2,284	-2,014	-3,563	-902	-2,510	-2,157	-1,416	-2,335	-2,368	-591	-1,813	-1,545
Share Based Compensation	-35.7%	202	314	214	586	317	405	309	655	681	656	511	935	302	465	1,613	464	313	340	304	212	318
Cashflow From Investing	1289.8%	3,950	-332	-221	-122	-169	-100	-104	-161	-137	-114	-74.00	-262	-188	-100	-30.00	-156	-87.00	-76.00	-114	-29.00	-200
Cashflow From Financing	-93.5%	125	1,921	-	-	22.00	161	46.00	126	161	314	-6,930	23,546	5,643	1,018	12,156	515	308	304	8,957	972	7,120

ICAD Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Revenue	$ 17,318	$ 19,802
Cost of Revenue:
Cost of revenue	2,533	2,983
Gross profit	14,785	16,819
Operating expenses:
Engineering and product development	5,161	5,493
Marketing and sales	7,740	10,790
General and administrative	9,324	10,517
Amortization and depreciation	249	217
Total operating expenses	22,474	27,017
Loss from operations	(7,689)	(10,198)
Other income (expense)
Interest expense	(16)	(10)
Interest income	729	213
Other	(14)	(39)
Other income, net	699	164
Loss before income tax expense	(6,990)	(10,034)
Benefit (provision) for income taxes	(20)	116
Loss from continuing operations	(7,010)	(9,918)
Income (loss) from discontinued operations	2,163	(3,738)
Net loss and comprehensive loss	$ (4,847)	$ (13,656)
Net loss per share:
Loss from continuing operations (in dollars per share)	$ (0.27)	$ (0.39)
Income (loss) from discontinued operations (in dollars per share)	0.08	(0.15)
Net loss per share, basic and diluted (in dollars per share)	$ (0.19)	$ (0.54)
Weighted average number of shares used in computing net loss per share:
Basic shares used in the calculation of earnings per share (in shares)	25,613	25,202
Diluted (in shares)	25,613	25,202
Product [Member]
Revenue:
Revenue	$ 9,930	$ 12,620
Cost of Revenue:
Cost of revenue	1,387	1,658
Service [Member]
Revenue:
Revenue	7,388	7,182
Cost of Revenue:
Cost of revenue	1,060	1,217
Amortization and Depreciation [Member]
Cost of Revenue:
Cost of revenue	$ 86	$ 108

ICAD Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 21,670,000	$ 21,313,000
Trade accounts receivable, net of allowance for credit losses of $277 in 2023 and $100 in 2022	6,392,000	5,769,000
Inventory, net	917,000	2,054,000
Prepaid expenses and other current assets	699,000	1,571,000
Current assets held for sale	0	7,534,000
Total current assets	29,678,000	38,241,000
Property and equipment:
Internal-use software	1,172,000	0
Equipment	1,482,000	1,421,000
Leasehold improvements	110,000	110,000
Furniture and fixtures and other	104,000	23,000
Property and equipment	2,868,000	1,554,000
Less accumulated depreciation and amortization	1,045,000	850,000
Property and equipment, net	1,823,000	704,000
Other assets:
Operating lease assets	461,000	670,000
Other assets	849,000	19,000
Intangible assets, net of accumulated amortization of $8,488 in 2023 and $8,372 in 2022	148,000	264,000
Goodwill	8,362,000	8,362,000
Deferred tax assets	97,000	116,000
Noncurrent assets held for sale	0	3,329,000
Total assets	41,418,000	51,705,000
Current liabilities:
Accounts payable	712,000	1,446,000
Accrued and other expenses	2,448,000	2,541,000
Lease payable, current	188,000	217,000
Deferred revenue, current	3,400,000	3,653,000
Current liabilities held for sale	0	5,595,000
Total current liabilities	6,748,000	13,452,000
Lease payable, long-term	273,000	455,000
Deferred revenue, long-term	974,000	393,000
Deferred tax	6,000	6,000
Noncurrent liabilities held for sale	0	2,497,000
Total liabilities	8,001,000	16,803,000
Commitments and contingencies (Note 16)
Stockholders’ equity:
Preferred stock, $ .01 par value: authorized 1,000,000 shares; none issued.	0	0
Common stock, $ .01 par value: authorized 60,000,000 shares; issued 26,540,030 in 2023 and 25,446,407 in 2022. Outstanding 26,354,199 in 2023 and 25,260,576 in 2022	265,000	254,000
Additional paid-in capital	306,250,000	302,899,000
Accumulated deficit	(271,683,000)	(266,836,000)
Treasury stock at cost, 185,831 shares in 2023 and 2022	(1,415,000)	(1,415,000)
Total stockholders’ equity	33,417,000	34,902,000
Total liabilities and stockholders’ equity	$ 41,418,000	$ 51,705,000

About Icad Inc

iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company's breast AI suite includes cancer detection, automated density assessment, and breast cancer risk assessment solutions for both 2D and 3D mammography. It offers PowerLook, a back-end architecture platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and PowerLook Density Assessment provides automated, consistent, and standardized breast density assessments. The company also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a clinical decision support tool that provides breast cancer risk estimation based on a screening mammogram; and VeraLook, a solution designed to support detection of colonic polyps in conjunction with Computed Tomography Colonography. In addition, it offers Xoft Axxent electronic brachytherapy systems for the treatment of early-stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

CEO	Ms. Dana R. Brown
WEBSITE	icadmed.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	108

Icad Inc Frequently Asked Questions

What is the ticker symbol for Icad Inc? What does ICAD stand for in stocks?

ICAD is the stock ticker symbol of Icad Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Icad Inc (ICAD)?

As of Fri Apr 19 2024, market cap of Icad Inc is 40.87 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ICAD stock?

You can check ICAD's fair value in chart for subscribers.

What is the fair value of ICAD stock?

You can check ICAD's fair value in chart for subscribers. The fair value of Icad Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Icad Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ICAD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Icad Inc a good stock to buy?

The fair value guage provides a quick view whether ICAD is over valued or under valued. Whether Icad Inc is cheap or expensive depends on the assumptions which impact Icad Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ICAD.

What is Icad Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, ICAD's PE ratio (Price to Earnings) is -8.43 and Price to Sales (PS) ratio is 2.16. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ICAD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Icad Inc's stock?

In the past 10 years, Icad Inc has provided -0.155 (multiply by 100 for percentage) rate of return.